# Safety and Efficacy of Pro-ocular™ 1% in Daily Scleral Lens Wearing Patients With Ocular Graft-versus-Host Disease

> **NCT04769648** · PHASE2,PHASE3 · UNKNOWN · sponsor: **Glia, LLC** · enrollment: 44 (actual)

## Conditions studied

- Ocular Graft-versus-host Disease

## Interventions

- **DRUG:** Pro-ocular™ Topical Gel 1%
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04769648
- **Lead sponsor:** Glia, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-04-15
- **Primary completion:** 2023-08-15
- **Final completion:** 2023-10-15
- **Target enrollment:** 44 (ACTUAL)
- **Last updated:** 2023-03-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04769648

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04769648, "Safety and Efficacy of Pro-ocular™ 1% in Daily Scleral Lens Wearing Patients With Ocular Graft-versus-Host Disease". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT04769648. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*